Regular Use of Depot Medroxyprogesterone Acetate Causes Thinning of the Superficial Lining and Apical Distribution of Human Immunodeficiency Virus Target Cells in the Human Ectocervix

J Infect Dis. 2022 Apr 1;225(7):1151-1161. doi: 10.1093/infdis/jiaa514.

Abstract

Background: The hormonal contraceptive depot medroxyprogesterone acetate (DMPA) may be associated with an increased risk of acquiring human immunodeficiency virus (HIV). We hypothesize that DMPA use influences the ectocervical tissue architecture and HIV target cell localization.

Methods: Quantitative image analysis workflows were developed to assess ectocervical tissue samples collected from DMPA users and control subjects not using hormonal contraception.

Results: Compared to controls, the DMPA group exhibited a significantly thinner apical ectocervical epithelial layer and a higher proportion of CD4+CCR5+ cells with a more superficial location. This localization corresponded to an area with a nonintact E-cadherin net structure. CD4+Langerin+ cells were also more superficially located in the DMPA group, although fewer in number compared to the controls. Natural plasma progesterone levels did not correlate with any of these parameters, whereas estradiol levels were positively correlated with E-cadherin expression and a more basal location for HIV target cells of the control group.

Conclusions: DMPA users have a less robust epithelial layer and a more apical distribution of HIV target cells in the human ectocervix, which could confer a higher risk of HIV infection. Our results highlight the importance of assessing intact genital tissue samples to gain insights into HIV susceptibility factors.

Keywords: DMPA; HIV; HIV target cells; digital image analysis; epithelial integrity; estradiol; female genital mucosa; hormonal contraception; in situ staining; progesterone.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Cervix Uteri / metabolism
  • Contraceptive Agents, Female* / adverse effects
  • Female
  • HIV
  • HIV Infections*
  • Humans
  • Medroxyprogesterone Acetate / adverse effects

Substances

  • Contraceptive Agents, Female
  • Medroxyprogesterone Acetate

Grants and funding